Though dual antagonist pairing (i.e., PD-1 x LAG3 and PD-1 x TIM3) seems to robustly enhance anti-tumour activity in the preclinical setting, heterodimerisation of different co-stimulatory receptors has to be studied in more detail (227–232). This evidence concerns the gene PDCD1 and neoplasm.